Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...
LLY's retatrutide posts strong weight-loss and pain-reduction results in its first Phase III study, boosting investor ...
The health sector witnesses significant developments with Eli Lilly's promising weight-loss drug trials and a $40 million ...
Regulators in Europe just backed Novo's heavyweight Wegovy--setting the stage for a head-to-head obesity drug showdown in ...
Investor's Business Daily on MSN
Eli Lilly leads five stocks near buy points in divided market
Eli Lilly, United Airlines and Urban Outfitters lead five stocks that are showing strength, near buy points, as AI stocks ...
Retatrutide, Eli Lilly’s triple-hormone obesity drug, delivers up to 28.7% weight loss and major knee pain relief in ...
Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.
Straight Arrow News on MSN
Eli Lilly touts strong results of new experimental weight loss drug retatrutide
Move over Ozempic, Wegovy, Mounjaro and Zepbound - Eli Lilly says another contender may be on the way. The pharmaceutical ...
Recent clinical trials of Novo Nordisk’s blockbuster GLP-1 drug semaglutide for Alzheimer’s disease may have failed to show ...
Investing.com -- Moody’s Ratings has affirmed Eli Lilly and Company ’s Aa3 senior unsecured notes ratings and long-term issuer rating while revising the outlook to positive from stable, the rating ...
Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to ...
The dramatic stock slump, which puts Novo Nordisk at a historically cheap valuation, reflects investor concern over future sales growth and competition, particularly from rival Eli Lilly & Co.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback